Navigate the Adolor ADLR Research Pages
- Introduction (valuation, financials, company outlook)
- Entereg (marketed hospital product used to accelerate GI function after bowel surgery)
- ADL5945 (phase 2 product candidate for opioid-induced constipation)
- Pipeline (details on earlier stage assets
ADL6906 (a.k.a. beloxepin)
- A dual seretonin receptor (5-HT2) antagonist and norepinephrine reuptake inhibitor
- Active in animal models of inflammatory, neuropathic, post-operative, and acute pain
- Previously studied by a large pharma in late stage trials for depression (1000+ pts with goof safety)...Appears to be Organon and called ORG 4428 - there are numerous scholarly journal articles referencing this compound
- 11/2010: ADLR is repositioning for pain
- 2/2011: mentioned phase 1 trial complete (but no details and does not show up on clinicaltrials.gov)
- 11/2010: Use patent issued for the treatment of pain, expires February 2029
- 2010 10k and 1q11 10q: have completed multi ascending dose p1 trial. Evaluating phase 2 plans, alone or w/ potential partner
- 4/6/11 webcast: this program is phase 2 ready for pain
Centrally-acting mu Opioid receptor (CAMOR) program
- Rationale: "Scientific evidence suggests that increased opioid peptide transmission in the basal ganglia might underlie dyskinesia after chronic l-DOPA treatment and that opioid antagonists might be useful as adjuncts to l-DOPA therapy for Parkinson's disease. Preclinical evaluation of opioid antagonists in non-human primate models of LID suggests that antagonism of the muopioid receptor may be effective for alleviating these l-DOPA-induced motor complications."
- 2010 10K: pts developed LID within 5-10 years of starting l-DOPA therapy
- 2/2011: briefly mentioned on 4q10 conference call
- 11/2010: Received grant from Michael J Fox Foundation for research in the program for l-DOPA induced dyskinesia (LID). $0.4m grant over 18 months will fund lead optimization studies of candidates that have demonstrated oral dosing and efficacy in preclinical primate LID models
Delta Opiod Receptor agonist program
- Goal: Obtain efficacy of compounds that target the Mu opiod receptors, but without the side effects
- Two compounds- ADL5849, ADL5747- failed in multiple phase 2 trials of osteoarthritis and neuropathic pain
- The program had been partnered to PFE, but they decided in December 2010 to terminate the deal effective March 2011 and abandon development of both candidates
- 2/2011: company confirmed that this program is abandoned